Document is current
Any future updates will be listed below
-
Authors
Tanaka, Yu
Nagano, China
Sakakibara, Nana
Okada, Eri
Aoyama, Shuhei
Kimura, Yuka
Inoki, Yuta
Ichikawa, Yuta
Ueda, Chika
Kitakado, Hideaki
Horinouchi, Tomoko
Yamamura, Tomohiko
Ishimori, Shingo
Iijima, Kazumoto
Nozu, Kandai
Morisada, Naoya https://orcid.org/0000-0003-2936-6615
-
Funding
Funding for this research was provided by:
H24-nanchi-ippan (041)
H29-nanchi-ippan (039)
23FC (1047)
23FC (1047)
KAKENHI (JP15K09261)
KAKENHI (22K08351)
KAKENHI (18K08243)
the Japan Agency for Medical Research and Development (23ek0109617s1702)
- License Information
-
More Information
Article History
Received: 11 December 2024
Accepted: 13 January 2025
First Online: 20 February 2025
Declarations
:
: All procedures involving human participants were performed in accordance with the ethical standards of the institutional and/or national research committee at which the studies were conducted (IRB approval numbers 86, 301, and 1210) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all the participants.
: Kazumoto Iijima received support from Zenyaku Kogyo Co., Ltd. Kandai Nozu is a member of advisory groups for Kyowa Kirin Co., Ltd., Toa Eiyo Ltd., Zenyaku Kogyo Co., Ltd., and Taisho Pharmaceutical Co., Ltd.. Kandai Nozu has received lecture fees from Ono Pharma, Astellas Pharma, Novo Nordisk Pharma, Alexion Pharma, Sumitomo Pharma, Sanofi, Otsuka Pharma, Daiichi Sankyo, and Miyarisan. Kandai Nozu received grants from Zenyaku Kogyo and Torii Co. Ltd..
